EP16.03-002 Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)

Abstract

Osimertinib is a third-generation EGFR-TKI approved for advanced NSCLC treatment, initially in the relapse scenario with T790M mutation but currently in the first-line setting. Effectiveness and safety have been studied in multiple clinical trials and observational studies; however, data regarding the Hispanic population and post-progression after Osimertinib treatment is scarce. In this study, we present the most significant real-world analysis of Osimertinib in the first line setting for NSCLC among Hispanic patients, with an in-depth analysis of post-progression results.